Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Hearing Loss

Tinnitus Talk submitted a new resource:

Safety, Tolerability and Efficacy for CGF166 in Patients With Bilateral Hearing Loss - To evaluate CGF166 delivered through IL-infusion to improve hearing and vestibular function.

Read more about this resource...

 

Found this today...
GenVec To Present At 2016 Cell & Gene Meeting On The Mesa

Wednesday, October 5th, 11 a.m. PDT/2:00 pm EDT
GAITHERSBURG, Md., Sept. 28, 2016 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC), a clinical-stage gene delivery company, announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, will present "Exploring the AdenoVerse™ Platform for New Advanced Cell and Gene Therapies", a brief review of GenVec's technology platform, at the 2016 Cell & Gene Meeting on the Mesa (CGMOM). This presentation will highlight new data that demonstrate the utility of select AdenoVerse vectors for efficient gene delivery to immune system cells, including T cells. GenVec believes that these vectors can be applied for therapeutic approaches focusing on genetically modified human primary T cells. GenVec has extensive expertise translating innovative product concepts from the laboratory to the clinic. The company's proprietary vectors are particularly well suited for the delivery of large therapeutic gene payloads, including gene editing technologies, for a wide a variety of treatment strategies.

Dr. Brough's presentation is scheduled for Wednesday, October 5, beginning at 11 a.m. PDT/2:00 p.m. EDT. A live video webcast of all company presentations at the CGMOM will be available at: www.meetingonthemesa.com/webcast during the proceedings; and the slides from Dr. Brough's presentation will be posted for review at www.genvec.com in the Media section, presentations collection. GenVec will post a video replay of Dr. Brough's talk on the company website at the same location when the video clip becomes available after the meeting concludes.

About GenVec

GenVec is a clinical-stage gene delivery company focused on developing a pipeline of cutting-edge therapeutics and vaccines using its proprietary AdenoVerse platform. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to its internal and partnered pipeline, the company is also focused on opportunities to license its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

 

Just to recall the reference of the clinical trial:
https://clinicaltrials.gov/ct2/show/NCT02132130
Status: Currently recruiting.
Results expected: June 2019.

Discussed in the thread:
https://www.tinnitustalk.com/threads/inner-ear-hair-cell-regeneration-—-maybe-we-can-know-more.3131/

See also the link from the company:
http://www.genvec.com/product-pipeline/cgf-166-hearing-loss